Clinical and molecular characterization of HER2 amplified-pancreatic cancer

Keywords

Geography, Political science

References

• HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapyDavid R. Engelke — 2009
• Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin)Peter Büchler, Howard A. Reber, Manuela C. Büchler — 2001
• Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the futureShayna L. Showalter, Sarah Charles, Justin Belin — 2010
• The BATTLE Trial: Personalizing Therapy for Lung CancerEdward S. Kim, Roy S. Herbst, Ignacio I. Wistuba — 2011
• Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu.Howard Safran, R. K. Ramanathan, Jazmin Schwartz — 2001
• Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumorsMatthew D. Galsky, Daniel D. Von Hoff, Marcus A. Neubauer — 2012
• Assessment of a HER2 scoring system for gastric cancer: results from a validation studyManfred Hofmann, O Stoss, Di Shi — 2008
• Long-term Survival and Metastatic Pattern of Pancreatic and Periampullary Cancer After Adjuvant Chemoradiation or Observation: Long-term Results of EORTC Trial 40891Hans G. Smeenk, Casper H.J. van Eijck, Wim C.J. Hop — 2007
• Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancerJan Harder, Gabriele Ihorst, Volker Heinemann — 2012
• Somatic variation and cancer: therapies lost in the mixAndrew V. Biankin, Thomas J. Hudson — 2011
• The molecular and cellular heterogeneity of pancreatic ductal adenocarcinomaNardin Samuel, Thomas J. Hudson — 2012
• Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.Yung‐Jue Bang, Eric Van Cutsem, A. Feyereislova — 2010
• Metastatic behavior of breast cancer subtypes.Hagen F. Kennecke, Rinat Yerushalmi, Ryan Woods — 2010
• DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.Christine A. Iacobuzio–Donahue, Baojin Fu, Shinichi Yachida — 2009
• Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.Laura J. Esserman, Donald A. Berry, Angela DeMichele — 2012
• International network of cancer genome projectsJennifer L. Jennings, Thomas J. Hudson, Arek Kasprzyk — 2010
• Supervised risk predictor of breast cancer based on intrinsic subtypes.Joel S. Parker, Michael E. Mullins, Maggie C.U. Cheang — 2009
• The prognostic and predictive value of serum CA19.9 in pancreatic cancerJeremy L. Humphris, David K. Chang, Amber L. Johns — 2012
• Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic AnalysesSiân Jones, Xiaosong Zhang, D. Williams Parsons — 2008
• Cancer Statistics, 2010Ahmedin Jemal, Rebecca L. Siegel, Jiaquan Xu — 2010

Cited by

• Next generation sequencing of pancreatic ductal adenocarcinoma: right or wrong?Francis Antonietti, Mullis Stefan — 2017
• Identification and characterization of downstream effector protein(s) regulated by p53 and pRbMiranda B. Carper — 2014
• HER2: An emerging biomarker in non-breast and non-gastric cancersNorhayati Omar, Benedict Yan, Manuel Salto‐Tellez — 2015
• Emerging Drug Target In Pancreatic Cancer: Placing Sirtuin 1 on the Canvas.Marc Giry-Laterrière, Andreia V. Pinho, Nils Eling — 2015
• Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trialEric Assénat, D. Azria, Caroline Mollévi — 2015
• HER2 expression in oesophageal carcinoma and Barrett's oesophagus associated adenocarcinoma: An Australian study.Vinayak Nagaraja, N. Shaw, Adrienne Morey — 2016
• Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapiesE. Gabriela Chiorean, Andrew L. Coveler — 2015
• Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacyBryan W. Miller, Jennifer P. Morton, Mark Pinese — 2015
• Mining the genomes of exceptional respondersDavid K. Chang, Sean M. Grimmond, T.R. Jeffry Evans — 2014
• HER2 aberrations in cancer: implications for therapy.Min Yan, Barbara A. Parker, Richard B. Schwab — 2014
• Assessing the role of the EGF receptor in the development and progression of pancreatic cancerMalcolm J. Moore, Natalie Cook, Kristopher K. Frese — 2014
• Role of vitamin D receptor gene polymorphisms in pancreatic cancer: a case–control study in ChinaLei Li, Feifei Shang, Weihui Zhang — 2015
• Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer.Julian Świerczyński — 2014
• Gene therapy in pancreatic cancer.Sixue Liu — 2014
• Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.Julian C. Schink, Julia R. Trosman, Christine B. Weldon — 2014
• MiRNAs and Their Interference with the Main Molecular Mechanisms Responsible for Drug Resistance in Pancreatic CancerIngrid Garajová, Elisa Giovannetti, S. Caponi — 2015
• Pancreatic cancer genomics.David K. Chang, Sean M. Grimmond, Andrew V. Biankin — 2014
• Molecular Mechanisms Underlying the Role of MicroRNAs in the Chemoresistance of Pancreatic CancerIngrid Garajová, Tessa Y. Le Large, Adam E. Frampton — 2014
• THE INDOLENT NATURE OF PULMONARY METASTASES FROM DUCTAL ADENOCARCINOMA OF THE PANCREASStephanie Downs‐Canner, Mazen S. Zenati, Brian A. Boone — 2015
• SOX9 regulates ERBB signalling in pancreatic cancer developmentAdrien Grimont, Andreia V. Pinho, Mark J. Cowley — 2014

Related papers

No related papers recorded.